Claims

1. Use of an activin receptor antagonist in the improvement of body composition in a human subject, whereby lean mass is increased, and fat mass is reduced, wherein the activin receptor antagonist is an anti-ActRII receptor antibody.

2. Use of an activin receptor antagonist in the treatment of central adiposity in a human subject, wherein said subject is obese, overweight or of normal BMI, wherein the activin receptor antagonist is an anti-ActRII receptor antibody.

3. Use of an activin receptor antagonist according to claim 1, wherein said patient has a BMI ≥ 30 kg/m^2, a BMI ≥ 25 and < 30 kg/m^2, or a BMI < 25.

4. Use of an activin receptor antagonist according to any of claims 1-3, wherein central adiposity is reduced.

5. Use of an activin receptor antagonist in the treatment, prevention or reduction of obesity or overweight condition and related comorbidities, wherein the activin receptor antagonist is an anti-ActRII receptor antibody.

6. Use of an activin receptor antagonist according to claim 5 wherein the treatment, prevention, or reduction of obesity or overweight condition reduces a related comordbidity, wherein the related comordibity isselected from the group of type 2 diabetes, glucose intolerance, prediabetes, insulin resistance, high triglycerides, physical impairment, osteoporosis , renal disease, obstructive sleep apnea, sexual hormones impairment, endocrine reproductive disorders such as polycystic ovary syndrome or male hypogonadism, osteoarthritis, gastrointestinal cancers, dyslipidaemia, hypertension, heart failure, coronary heart disease, stroke, gallstones, and altered gonadal hormone profile.

7. Use of an activin receptor antagonist according to claims 5-6 for the treatment, reduction or prevention of type II diabetes.

8. Use of an activin receptor antagonist according to claims 1 or 3, wherein improvement of body composition comprises reduction of central adiposity.

9. Use of an activin receptor antagonist according to claim 8, for the prevention of type II diabetes and treatment of obesity or overweight condition.

10. Use of an activin receptor antagonist according to claim 9, for improving glycemic control.

11. An activin receptor antagonist in improving glycemic control in a patient suffering from type II diabetes, wherein the activin receptor antagonist is an anti-ActRII receptor antibody.

12. Use of an activin receptor antagonist according to claim 11, wherein improving glycemic control is achieved by improving insulin sensitivity.

13. Use of an activin receptor antagonist according to claims 11-12, wherein the patient is suffering from obesity or overweight condition.

14. Use of an activin receptor antagonist according to claim 13 wherein the DTSQ score (Diabetes treatment satisfaction questionnaire score, or IWQOL/IWQOL-lite (Impact of Weight on Quality of Life) score or other patient related outcome (PRO) related to obesity and/or diabetes are improved.

15. Use of an activin receptor antagonist according to any claims 1-14 wherein anti-ActRII receptor antibody comprises the complentarity-determining regions (CDRS) of SEQ ID NOS: 1-6.

16. Use of an activin receptor antagonist according to any of claims 1-15, wherein the anti- ActRII receptor antibody comprises the light chain of SEQ ID NOS: 7 or 8 and the heavy chain of SEQ ID NO: 9.

.

17. Use of an activin receptor antagonist according to any of the claims 1-16 wherein the anti-ActRII receptor antibody is bimagrumab.

18. Use of an activin receptor antagonist according to any of claims 1-17 wherein the anti- ActRII receptor antibody is administered at a dose of 3 mg/kg or 10 mg/kg.

19. Use of an activin receptor antagonist according to any claims 1-18, wherein the anti-ActRII receptor antibody is administered every 4 weeks.

20. Use of an activin receptor antagonist according to any claims 1-18, wherein the anti-ActRII receptor antibody is administered at a dose of 3mg/kg or 10mg/kg, and wherein the anti-ActRII receptor antibody is administered every 4 weeks.